Human evidence record · CJC-1295 (with DAC)

CJC-1295 increases GH and IGF-I in healthy adults

GH increased approximately 2-10-fold for at least 6 days and IGF-I about 1.5-3-fold for 9-11 days; estimated half-life 5.8-8.1 days.

Quick read

Human evidence record

What this study tells us

Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.

Who was studied?

Healthy adults

How many?

Not clearly reported in the indexed source used for this record.

What happened?

GH increased approximately 2-10-fold for at least 6 days and IGF-I about 1.5-3-fold for 9-11 days; estimated half-life 5.8-8.1 days.

What stops us overclaiming?

Hormone target engagement is not evidence of meaningful lifestyle outcomes.

Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →

Key result

GH increased approximately 2-10-fold for at least 6 days and IGF-I about 1.5-3-fold for 9-11 days; estimated half-life 5.8-8.1 days.

Study details

Study designTwo randomized placebo-controlled dose-escalation studies

PhasePhase I

PopulationHealthy adults

RouteSubcutaneous

Regimen / exposureSingle ascending doses and repeated weekly/biweekly dosing

DurationUp to several weeks

ComparatorPlacebo

Primary endpoint / questionGH and IGF-I pharmacodynamics

Safety resultEarly pharmacology studies; not designed to establish body-composition or anti-ageing benefit.

Key limitationsHormone target engagement is not evidence of meaningful lifestyle outcomes.

Registry / identifierPMID 16352683

Open CJC-1295 (with DAC) page →Open primary source →